Amphastar Pharmaceuticals SG&A Expenses 2012-2024 | AMPH

Amphastar Pharmaceuticals sg&a expenses from 2012 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
Amphastar Pharmaceuticals Annual SG&A Expenses
(Millions of US $)
2023 $80
2022 $67
2021 $69
2020 $65
2019 $63
2018 $58
2017 $51
2016 $47
2015 $47
2014 $40
2013 $36
2012 $32
2011 $31
2009 $13
Amphastar Pharmaceuticals Quarterly SG&A Expenses
(Millions of US $)
2024-03-31 $25
2023-12-31 $22
2023-09-30 $19
2023-06-30 $19
2023-03-31 $21
2022-12-31 $16
2022-09-30 $17
2022-06-30 $16
2022-03-31 $18
2021-12-31 $15
2021-09-30 $16
2021-06-30 $19
2021-03-31 $20
2020-12-31 $16
2020-09-30 $15
2020-06-30 $20
2020-03-31 $14
2019-12-31 $14
2019-09-30 $14
2019-06-30 $15
2019-03-31 $19
2018-12-31 $16
2018-09-30 $15
2018-06-30 $14
2018-03-31 $13
2017-12-31 $11
2017-09-30 $13
2017-06-30 $14
2017-03-31 $13
2016-12-31 $12
2016-09-30 $12
2016-06-30 $11
2016-03-31 $12
2015-12-31 $10
2015-09-30 $10
2015-06-30 $13
2015-03-31 $14
2014-12-31 $11
2014-09-30 $11
2014-06-30 $10
2014-03-31 $8
2013-12-31 $9
2013-09-30 $11
2013-06-30 $8
2013-03-31 $8
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.020B $0.644B
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.160B 6.68
Dr Reddy's Laboratories (RDY) India $11.626B 17.29
Aspen Pharmacare (APNHY) South Africa $5.507B 0.00
BridgeBio Pharma (BBIO) United States $5.417B 0.00
Bausch Health Cos (BHC) Canada $2.612B 1.99
Supernus Pharmaceuticals (SUPN) United States $1.593B 0.00
Taysha Gene Therapies (TSHA) United States $0.481B 0.00
Generation Bio (GBIO) United States $0.236B 0.00
Personalis (PSNL) United States $0.079B 0.00
Assembly Biosciences (ASMB) United States $0.077B 0.00
Acasti Pharma (ACST) Canada $0.026B 0.00
Sol-Gel Technologies (SLGL) Israel $0.018B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00